A detailed history of Gsa Capital Partners LLP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 56,754 shares of IGMS stock, worth $554,486. This represents 0.07% of its overall portfolio holdings.

Number of Shares
56,754
Previous 61,981 8.43%
Holding current value
$554,486
Previous $426,000 120.42%
% of portfolio
0.07%
Previous 0.03%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$6.28 - $17.68 $32,825 - $92,413
-5,227 Reduced 8.43%
56,754 $939,000
Q2 2024

Aug 15, 2024

BUY
$6.51 - $11.47 $283,725 - $499,897
43,583 Added 236.89%
61,981 $426,000
Q1 2024

May 03, 2024

BUY
$8.68 - $17.36 $159,694 - $319,389
18,398 New
18,398 $177,000
Q3 2023

Nov 15, 2023

BUY
$6.66 - $10.64 $175,544 - $280,449
26,358 Added 24.65%
133,276 $1.11 Million
Q2 2023

Aug 14, 2023

BUY
$8.86 - $14.0 $529,234 - $836,262
59,733 Added 126.59%
106,918 $986,000
Q1 2023

May 12, 2023

BUY
$13.74 - $25.76 $238,031 - $446,266
17,324 Added 58.02%
47,185 $648,000
Q4 2022

Feb 13, 2023

BUY
$15.45 - $26.02 $180,486 - $303,965
11,682 Added 64.26%
29,861 $508,000
Q3 2022

Nov 14, 2022

SELL
$15.42 - $27.01 $57,639 - $100,963
-3,738 Reduced 17.06%
18,179 $413,000
Q2 2022

Aug 09, 2022

SELL
$13.27 - $25.5 $193,742 - $372,300
-14,600 Reduced 39.98%
21,917 $395,000
Q1 2022

May 11, 2022

BUY
$13.42 - $29.73 $387,126 - $857,621
28,847 Added 376.1%
36,517 $976,000
Q4 2021

Feb 14, 2022

BUY
$27.59 - $66.39 $62,491 - $150,373
2,265 Added 41.91%
7,670 $225,000
Q3 2021

Nov 12, 2021

BUY
$65.76 - $90.65 $33,471 - $46,140
509 Added 10.4%
5,405 $355,000
Q2 2021

Aug 05, 2021

BUY
$57.98 - $96.6 $61,690 - $102,782
1,064 Added 27.77%
4,896 $407,000
Q1 2021

May 10, 2021

SELL
$71.56 - $121.23 $194,571 - $329,624
-2,719 Reduced 41.51%
3,832 $294,000
Q4 2020

Feb 03, 2021

BUY
$47.41 - $115.03 $310,582 - $753,561
6,551 New
6,551 $578,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $283M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.